GeneDx Holdings Investor Alert: Class Action Lawsuit Deadline Approaching
A securities litigation firm is investigating claims against GeneDx Holdings for allegedly misleading investors about an acquisition and synergy potential. Investors have a deadline to join the class action lawsuit.
National securities litigation firm Hagens Berman is investigating claims in a securities class action lawsuit against GeneDx Holdings and its executives. The suit alleges the company misled investors regarding its acquisition of Fabric Genomics and its synergy potential.
The lawsuit follows a significant stock price collapse of 49% on May 5, 2026, in response to the company's poor first-quarter 2026 earnings report. This report included a substantial $31.2 million impairment charge, primarily linked to the Fabric Genomics business, which reportedly missed revenue targets and was a major contributor to the losses.
The deadline for investors to be appointed as lead plaintiff in the class action is August 3, 2026. The company recently appointed a new President, Mark Gardner, following the stock's downturn. Hagens Berman is examining whether this leadership change is related to alleged failures preceding the May stock collapse.
The firm alleges investors were presented with a "vision of technological synergy, only to be hit with a massive impairment charge." Hagens Berman is investigating whether GeneDx's leadership was aware of a disconnect between public projections and the internal reality of its acquisitions. Investors who suffered significant losses are urged to contact the firm.